Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00588276 · ClinicalTrials.gov registry record · Phase 1

Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors

A Phase 1 study of Cervical Cancer and Renal Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Completed
Registry status
Phase 1
Development phase
15
Enrollment target
1
Study location

NCT00588276 is a Phase 1 study of Cervical Cancer and Renal Cancer that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 15 participants, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00588276, a Phase 1 study of Cervical Cancer and Renal Cancer, has completed, sponsored by Memorial Sloan Kettering Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate low oxygen areas called hypoxia within the tumor. These low oxygen areas are thought to be the reason why tumors are more resistant to radiation treatment. A tracer is an extremely small quantity of a substance. Tracer to which radioactivity has been attached may be used to "trace" events in the body. A tracer called iodo-azomycin galactopyranoside (or \*IAZGP) appears to be able to detect low oxygen areas within tumor. Radioactive iodine in this molecule can be detected by an imaging technique called a PET scan. This present study involves obtaining three scans using this new imaging technique. The goal of carrying out many scans is to determine which scan will best show any areas in your tumor that may have low levels of oxygen.

Conditions Studied

Cervical Cancer Renal Cancer Uterine Cancer RECTUM HEENT Cancer Cervix Uteri NOS

Interventions

  • RADIATION 124I-Iodo-Azomycin Galacto-Pyranoside

Study Locations (1)

New York

  • Memorial Sloan-Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2005-06
Est. Completion 2012-06
Phase Phase 1

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00588276

The ClinicalTrials.gov registry entry for NCT00588276 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Cervical Cancer appearing as the primary indexed condition, and to 1 intervention - of which 124I-Iodo-Azomycin Galacto-Pyranoside is the first listed.

NCT00588276 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT00588276 about?

NCT00588276 is a clinical study titled "Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors". The purpose of this study is to evaluate low oxygen areas called hypoxia within the tumor. These low oxygen areas are thought to be the reason why tumors are more resistant to radiation treatment. A tracer is an extremely small quantity of a substance. Tracer to which radioactivity has been attached...

What is the current status of trial NCT00588276?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2005-06. Estimated completion is 2012-06.

What conditions does trial NCT00588276 study?

This clinical trial studies the following conditions: Cervical Cancer, Renal Cancer, Uterine Cancer, RECTUM, HEENT Cancer.

What interventions are being tested in trial NCT00588276?

The interventions under investigation include: 124I-Iodo-Azomycin Galacto-Pyranoside (RADIATION).

Who is sponsoring clinical trial NCT00588276?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00588276 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cervical Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cervical Cancer

All registered trials for this condition

Renal Cancer

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.